Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491005 | 0.92 | ALOX5 (1.00) | ALOX5TDP1APPAKR1B10AKR1B1 | |
| SCHEMBL2540241 | 0.83 | TDP1 (0.85) | ALOX5TDP1APPLMNAMAPT | |
| SCHEMBL20940489 | 0.82 | ALOX5 (1.00) | ALOX5AKR1B1TRPV1MAPT | |
| SCHEMBL491168 | 0.82 | ALOX5 (0.81) | ALOX5TDP1APPMAPT | |
| SCHEMBL18061539 | 0.80 | ALOX5 (0.62) | ALOX5TDP1TNKS2APPMET | |
| SCHEMBL18061536 | 0.80 | ALOX5 (0.62) | ALOX5TDP1TNKS2APPMET | |
| SCHEMBL29641938 | 0.80 | ALOX5 (0.54) | ALOX5TNKS2APPMETLMNA | |
| SCHEMBL490945 | 0.80 | ALOX5 (0.77) | ALOX5TDP1APPMETTRPV1 | |
| SCHEMBL490871 | 0.79 | ALOX5 (0.76) | ALOX5TDP1APP | |
| SCHEMBL7319637 | 0.79 | TDP1 (0.75) | TDP1APPAKR1B10AKR1B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4276089-A2 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | Universite De Moncton (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | disclosed |
| EP-3423429-B1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIV DE MONCTON (CA) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | ALOX12, ALOX15B, ALOX5 | ALOX5 3/4885TDP1 2457/4885TNKS2 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.